Repurposing antimalarials and other drugs for COVID-19.
作者信息
Schlagenhauf Patricia, Grobusch Martin P, Maier Julian D, Gautret Philippe
机构信息
University of Zurich Centre for Travel Medicine, WHO Collaborating for Travellers' Health, Department of Public and Global Health, Institute for Epidemiology, Biostatistics and Prevention, Hirschengraben 84, 8001, Zurich, Switzerland.
Center of Tropical Medicine and Travel Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, the Netherlands.
出版信息
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
Abstract
摘要
相似文献
1
Repurposing antimalarials and other drugs for COVID-19.将抗疟药及其他药物重新用于治疗新冠肺炎。
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
2
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.药物重定位是治疗冠状病毒 COVID-19 的一种替代方法。
Int J Antimicrob Agents. 2020 Jun;55(6):105969. doi: 10.1016/j.ijantimicag.2020.105969. Epub 2020 Apr 9.
3
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
4
Treatments for COVID-19: where are we now?2019冠状病毒病的治疗方法：我们目前处于什么阶段？
Br J Community Nurs. 2020 Aug 2;25(8):412-413. doi: 10.12968/bjcn.2020.25.8.412.
5
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
6
Uncertainty about the Efficacy of Remdesivir on COVID-19.瑞德西韦对COVID-19疗效的不确定性。
J Korean Med Sci. 2020 Jun 15;35(23):e221. doi: 10.3346/jkms.2020.35.e221.
7
Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.瑞德西韦的紧急使用授权：透明分配流程的必要性。
JAMA. 2020 Jun 16;323(23):2365-2366. doi: 10.1001/jama.2020.8863.
8
Audio Interview: New Data on Remdesivir in Covid-19.音频访谈：瑞德西韦治疗新冠病毒病的新数据
N Engl J Med. 2020 May 28;382(22):e94. doi: 10.1056/NEJMe2019975.
9
Communicating Science in the Time of a Pandemic.疫情时期的科学传播
JAMA. 2020 Aug 4;324(5):443-444. doi: 10.1001/jama.2020.12535.
10
Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.瑞德西韦用于治疗COVID-19的孤儿药指定的政策影响
JAMA Intern Med. 2020 Oct 1;180(10):1273-1274. doi: 10.1001/jamainternmed.2020.2759.
引用本文的文献
1
Efficacy and Safety of Antimalarial as Repurposing Drug for COVID-19 Following Retraction of Chloroquine and Hydroxychloroquine.氯喹和羟氯喹撤稿后抗疟药作为COVID-19重新利用药物的疗效和安全性
Clin Pharmacol. 2025 Jan 16;17:1-11. doi: 10.2147/CPAA.S493750. eCollection 2025.
2
In silico Drug Repurposing of Anticancer Drug 5-FU and Analogues Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics Simulation, Pharmacokinetics and Chemical Reactivity Studies.抗癌药物5-氟尿嘧啶及其类似物针对新型冠状病毒主蛋白酶的计算机辅助药物重新设计：分子对接、分子动力学模拟、药代动力学和化学反应性研究
Adv Appl Bioinform Chem. 2022 Aug 15;15:59-77. doi: 10.2147/AABC.S366111. eCollection 2022.
3
Covid 19-the 21st Century Pandemic: The Novel Coronavirus Outbreak and the Treatment Strategies.新冠疫情——21世纪的大流行：新型冠状病毒爆发及治疗策略
Adv Pharm Bull. 2022 Jan;12(1):34-44. doi: 10.34172/apb.2022.005. Epub 2021 Jan 30.
4
Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M) as Potential COVID-19 Therapies.针对严重急性呼吸综合征冠状病毒2型主要蛋白酶（M）的药物和天然产物的计算性重新利用作为潜在的新冠肺炎治疗方法
Front Mol Biosci. 2022 Mar 14;9:781039. doi: 10.3389/fmolb.2022.781039. eCollection 2022.
5
Antiviral peptides against the main protease of SARS-CoV-2: A molecular docking and dynamics study.针对新型冠状病毒主要蛋白酶的抗病毒肽：分子对接与动力学研究。
Arab J Chem. 2021 Sep;14(9):103315. doi: 10.1016/j.arabjc.2021.103315. Epub 2021 Jul 14.
6
Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.医护人员血清调查为羟氯喹预防 SARS-CoV-2 感染的有效性提供了支持性证据。
J Epidemiol Glob Health. 2021 Sep;11(3):283-288. doi: 10.2991/jegh.k.210518.001. Epub 2021 May 23.
7
Drug repurposing against coronavirus disease 2019 (COVID-19): A review.针对2019冠状病毒病（COVID-19）的药物重新利用：综述
J Pharm Anal. 2021 Dec;11(6):683-690. doi: 10.1016/j.jpha.2021.09.001. Epub 2021 Sep 4.
8
Interpreting the impact of hydroxychloroquine prophylaxis on SARS-CoV-2 infection.解读羟氯喹预防对严重急性呼吸综合征冠状病毒2感染的影响。
Indian J Med Res. 2021 May;153(5&6):564-565. doi: 10.4103/ijmr.ijmr_1092_21.
9
Recent updates on the possible reasons for the low incidence and morbidity of COVID-19 cases in Africa.关于非洲新冠病毒疾病（COVID-19）病例低发病率和低死亡率可能原因的最新情况。
Bull Natl Res Cent. 2021;45(1):133. doi: 10.1186/s42269-021-00589-9. Epub 2021 Jul 23.
10
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.SARS-CoV-2/COVID-19 大流行管理的潜在治疗靶点和疫苗开发：近期进展综述。
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
本文引用的文献
1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
2
Covid-19 and community mitigation strategies in a pandemic.新冠疫情期间的新冠病毒病与社区缓解策略
BMJ. 2020 Mar 17;368:m1066. doi: 10.1136/bmj.m1066.
3
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
4
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
5
Remdesivir as a possible therapeutic option for the COVID-19.瑞德西韦作为治疗新冠肺炎的一种可能选择。
Travel Med Infect Dis. 2020 Mar-Apr;34:101615. doi: 10.1016/j.tmaid.2020.101615. Epub 2020 Mar 5.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
8
Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.德国一名无症状接触者传播2019新型冠状病毒感染
N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30.
9
A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).中东呼吸综合征冠状病毒（MERS-CoV）治疗药物的系统评价。
Travel Med Infect Dis. 2019 Jul-Aug;30:9-18. doi: 10.1016/j.tmaid.2019.06.012. Epub 2019 Jun 25.
10
Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study.撒哈拉以南非洲非免疫旅行者疟疾化学预防的耐受性：多中心、随机、双盲、四臂研究。
BMJ. 2003 Nov 8;327(7423):1078. doi: 10.1136/bmj.327.7423.1078.
Zotero 插件